GLP-1 agonists, like semaglutide, replicate the function of the natural hormone GLP-1 in the body
A starting tirzepatide dose of 2.5 milligrams roughly corresponds to the starting semaglutide dose of 0.25 milligrams in terms of tolerability and initial effect
A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of certain cancers through improved insulin regulation and immune modulation
Terauchi Y, Fujiwara H, Kurihara Y, Suganami H, Tamura M, Senda M, et al
Look for small opportunities to move
If you become dehydrated, your kidney function may worsen, so drink enough fluids unless your doctor has told you to restrict them